Literature DB >> 32367275

A case of reactive lymphoid hyperplasia of the liver in a patient with autoimmune hepatitis.

Hiroki Kanno1, Hisamune Sakai2, Toru Hisaka2, Satoki Kojima2, Ryuta Midorikawa2, Shogo Fukutomi2, Yoriko Nomura2, Yuichi Goto2, Toshihiro Sato2, Munehiro Yoshitomi2, Ryuichi Kawahara2, Koji Okuda2.   

Abstract

BACKGROUND: Reactive lymphoid hyperplasia (RLH) of the liver is a benign disorder. It is usually observed in the skin, orbit, thyroid, lung, breast, or gastrointestinal tract, but rarely in the liver. Since the first report of RLH of the liver in 1981, only 75 cases have been described in the past literature. Herein, we report a case of RLH of the liver in a patient with autoimmune hepatitis (AIH), which was misdiagnosed as hepatocellular carcinoma (HCC) preoperatively and resected laparoscopically. CASE
PRESENTATION: A 43-year-old Japanese woman with autoimmune hepatitis was followed up for 5 years. During her medical checkup, a hypoechoic nodule in segment 6 of the liver was detected. The nodule had been gradually increasing in size for 4 years. Abdominal ultrasound (US) revealed a round, hypoechoic nodule, 12 mm in diameter. Contrast-enhanced computed tomography (CT) demonstrated that the nodule was slightly enhanced in the arterial dominant phase, followed by perinodular enhancement in the portal and late phases. A magnetic resonance imaging (MRI) scan showed low signal intensity on the T1-weighted image (T1WI) and slightly high signal intensity on the T2-weighted image (T2WI). The findings of the Gd-EOB-DTPA-enhanced MRI were similar to those of contrast-enhanced CT. Tumor markers were all within the normal range. The preoperative diagnosis was HCC and a laparoscopic right posterior sectionectomy was performed. Pathological examination revealed that the nodular lesion was infiltrated by small lymphocytes and plasma cells, and germinal centers were present. Immunohistochemistry was positive for B cell and T cell markers, indicating polyclonality. The final diagnosis was RLH of the liver.
CONCLUSIONS: The pathogenesis of RLH of the liver remains unknown, and a definitive diagnosis based on imaging findings is extremely difficult. If a small, solitary nodule is found in female patients with AIH, the possibility of RLH of the liver should be considered.

Entities:  

Keywords:  Autoimmune hepatitis; Liver; Reactive lymphoid hyperplasia

Year:  2020        PMID: 32367275      PMCID: PMC7198675          DOI: 10.1186/s40792-020-00856-3

Source DB:  PubMed          Journal:  Surg Case Rep        ISSN: 2198-7793


Background

Reactive lymphoid hyperplasia (RLH), also called pseudolymphoma or nodular lymphoid lesions, of the liver is a benign disorder. It is characterized by a marked proliferation of non-neoplastic polyclonal lymphocytes forming follicles with active germinal centers. RLH is usually observed in the skin, orbit, thyroid, lung, breast, or gastrointestinal tract, but rarely in the liver. Since the first report of RLH of the liver in 1981 by Snover et al. [1], only 75 cases have been described in the past literature. Etiology and pathogenesis of RLH of the liver is completely unknown. Herein, we report a case of RLH of the liver in a patient with autoimmune hepatitis (AIH), which was misdiagnosed as hepatocellular carcinoma (HCC) preoperatively and resected laparoscopically.

Case presentation

A 43-year-old Japanese woman was followed for AIH for 5 years and has been prescribed oral steroids. She had a medical history of cerebral hemorrhage. During her medical checkup, a hypoechoic nodule in segment 6 (S6) of the liver was detected by abdominal ultrasound (US). It was initially diagnosed as a simple cyst. The nodule gradually increased from 7 mm to 12 mm in diameter over a 4-year period. On physical examination, there were no abnormalities. A laboratory examination showed no remarkable abnormalities: aspartate aminotransferase 19 U/L, alanine aminotransferase 19 U/L, alkaline phosphatase 168 U/L, γ-glutamyltransferase 11 U/L, total bilirubin 0.5 mg/dl, albumin 3.90 g/dl, platelet counts 32.1 × 104/μl, and prothrombin time 113%. Serum IgG level was 2566 mg/dl. Tumor markers were within normal range: α-fetoprotein 1.2 ng/ml, protein-induced vitamin K absence-II 16.0 mAU/ml, carcinoembryonic antigen 0.3 ng/ml, and carbohydrate antigen 19-9 8.1 U/ml. Hepatitis virus markers were all negative. Abdominal US revealed a round hypoechoic homogeneous nodule, 12 mm in diameter (Fig. 1). It was enhanced in the arterial dominant phase followed by defected in the post vascular phase by the contrast medium. Plain computed tomography (CT) showed low density in S6 of the liver and contrast-enhanced CT demonstrated that the nodule was slightly enhanced in the arterial dominant phase followed by perinodular enhancement in the portal and late phases (Fig. 2). Magnetic resonance imaging (MRI) showed low signal intensity on the T1-weighted image (T1WI) and slightly high signal intensity on the T2-weighted image (T2WI). On the diffusion-weighted image (DWI), the lesion showed high signal intensity. Gadolinium ethoxybenzyl diethlenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI showed similar findings as contrast-enhanced CT and subsequently presented the defect in the hepatobiliary phase (Fig. 3).
Fig 1

Abdominal ultrasound reveals a well-demarcated, homogenous, hypoechoic round nodule in segment 6 of the liver

Fig. 2

On CT, the nodule is slightly enhanced in the arterial dominant phase (a). The lesion shows perinodular enhancement in the portal and delayed phases (b, c) (white arrow)

Fig. 3

MRI demonstrates that the nodule shows well-defined low signal intensity in T1-weighted image (a), slightly high signal intensity in T2-weighted image (b), and strongly high signal intensity in diffusion-weighted image (c). Gd-EOB-DTPA-enhanced MRI reveals that the nodule is slightly enhanced in the arterial phase (d). The lesion shows perinodular enhancement in the portal phase (e) and a defect in hepatobiliary phase (f) (white arrowhead)

Abdominal ultrasound reveals a well-demarcated, homogenous, hypoechoic round nodule in segment 6 of the liver On CT, the nodule is slightly enhanced in the arterial dominant phase (a). The lesion shows perinodular enhancement in the portal and delayed phases (b, c) (white arrow) MRI demonstrates that the nodule shows well-defined low signal intensity in T1-weighted image (a), slightly high signal intensity in T2-weighted image (b), and strongly high signal intensity in diffusion-weighted image (c). Gd-EOB-DTPA-enhanced MRI reveals that the nodule is slightly enhanced in the arterial phase (d). The lesion shows perinodular enhancement in the portal phase (e) and a defect in hepatobiliary phase (f) (white arrowhead) The preoperative diagnosis was HCC. Because there was a risk of intraabdominal seeding, we did not perform percutaneous needle biopsy of the nodule. The patient received laparoscopic right posterior sectionectomy. The cut section of the resected liver showed a well-demarcated, round, yellowish-white lesion measuring about 14 mm. Pathological examination revealed a nodular lesion without fibrous capsule. The lesion was infiltrated by small lymphocytes and plasma cells, and germinal centers were present (Fig. 4a). Marked lymphoid cell infiltration was found in the portal tracts around the nodule (Fig. 4b). Although many small granulomas were found in the lesion, infectious pathogens were not found on periodic acid-Schiff, Gomori-Grocott, or Ziehl-Neelsen stainings. Immunohistochemical staining revealed that the follicles were CD20-positive. The lymphocytes in the germinal centers were CD10-positive and Bcl-2-negative. The interfollicular area was composed of CD3-positive small T cells. Infiltrating plasma cells showed a polyclonal expression of cellular immunoglobulin kappa and lambda chains (Fig. 5). Some IgG4-positive plasma cells were present, but most were IgG-positive plasma cells. The final diagnosis was RLH of the liver.
Fig. 4

Pathological examination reveals that germinal centers are present and small lymphocytes and plasma cells are infiltrating the lesion (a). Marked lymphoid cell infiltration in the portal tracts was observed in the perinodular lesion (b)

Fig. 5

Immunohistochemical staining reveals that the follicles are CD20-positive. The lymphocytes in the germinal centers are CD10-positive and Bcl-2-negative. The interfollicular area is composed of CD3-positive small T cells. Infiltrating plasma cells show a polyclonal expression of cellular immunoglobulin kappa and lambda chains

Pathological examination reveals that germinal centers are present and small lymphocytes and plasma cells are infiltrating the lesion (a). Marked lymphoid cell infiltration in the portal tracts was observed in the perinodular lesion (b) Immunohistochemical staining reveals that the follicles are CD20-positive. The lymphocytes in the germinal centers are CD10-positive and Bcl-2-negative. The interfollicular area is composed of CD3-positive small T cells. Infiltrating plasma cells show a polyclonal expression of cellular immunoglobulin kappa and lambda chains The post-operative course was uneventful and she was discharged on post-operative day nine.

Discussion

RLH of the liver is rare. Based on a review of the PubMed database from 1981 to 2019 using the keywords “Reactive lymphoid hyperplasia,” “Pseudolymphoma,” and “Liver,” we found 75 cases of RLH of the liver [1-51]. These cases, along with our case, are summarized in Table 1. Of the 76 cases, 71 (93.4%) were female. The average patients’ age was 56.7 years old (range, 15–85). Among them, 35.5% had liver diseases, 17.1% had autoimmune disease, and 27.6% had a malignant tumor. Many were solitary (84.7%), the average size being 16.3 mm (range, 4–105 mm) and 81.3% of the tumors were less than 20 mm in diameter. Many were located in the right lobe (62.9%). 93.1% were diagnosed as malignant tumors such as HCC, cholangiocellular carcinoma (CCC), or metastatic. Surgical resection was performed in 82.9% of cases. US findings showed most of the lesions were round and hypoechoic. Plain CT revealed low density and findings on contrast-enhanced CT ranged from enhanced to slightly enhanced to perinodular enhancement. On MRI, almost all lesions were found to have low intensity on T1WI and high intensity on T2WI and presented various enhancement patterns similar to the CT findings.
Table 1

Clinicopathological features of reactive lymphoid hyperplasia of the liver

Variablesn = 76Percentage
Clinical characteristics
 Age (ave, range)56.7 (15–85)
 Sex
  Male56.6
  Female7193.4
 Liver diseases35.5
  Viral hepatitis B6
  Viral hepatitis C2
  Primary biliary cirrhosis14
  Non-alcoholic steatohepatitis2
  Autoimmune hepatitis3
 Autoimmune disorders17.1
  Chronic thyroiditis4
  Sjögren’s syndrome3
  Rheumatoid arthritis1
  Takayasu disease1
  Antiphospholipid syndrome1
  CREST syndrome1
  Immunodeficiency2
 Malignant tumor27.6
  Colon cancer6
  Gastric cancer5
  Renal cell carcinoma4
  Cervical cancer1
  Thyroid cancer1
  Bile duct cancer1
  Pancreatic cancer1
  Ovarian cancer1
  GIST1
 Number of nodules
  Solitary6184.7
  Multiple1115.3
 Nodule size (ave, range) (mm)
  < 206581.3
  ≥ 201518.7
 Location
  Rt. lobe3962.9
  Lt. lobe1524.2
  Caudate lobe34.8
  Bilobar58.1
 Preoperative diagnosis
  Hepatocellular carcinoma3153.4
  Cholangiocellular carcinoma46.9
  Metastatic1220.7
  Malignant tumor712.1
  Others46.9
 Treatment
  Operation6382.9
  Biopsy810.5
  Transplantation33.9
  Others22.6
Imaging findings (described)
 US
  Hypo3951.3
  Iso11.3
  Unknown3647.4
 CT (plain)
  Low2938.2
  Not detected22.6
  Unknown4559.2
 CT (arterial phase)
  Enhanced1519.7
  Slightly enhanced1519.7
  Perinodular enhancement911.8
  Not enhanced56.6
  Unknown3242.1
 CT (portal or delay phase)
  Washout2330.3
  Perinodular enhancement810.5
  Not enhanced45.3
  Others56.6
  Unknown3647.4
 MRI (T1WI)
  Hypo4255.3
  Slightly hypo45.3
  Unknown3039.5
 MRI (T2WI)
  Hyper3850.0
  Slightly hyper56.6
  Iso33.9
  Unknown3039.5
MRI (arterial phase)
 Enhanced1317.1
 Slightly enhanced1418.4
 Perinodular enhancement810.5
 Others33.9
 Unknown3850.0
MRI (portal or delay phase)
 Washout1925.0
 Perinodular enhancement810.5
 Others33.9
 Unknown4660.5
 PET
  Positive810.5
   SUV max (ave, range, n = 6)4.9(3.4–6.7)
  Negative22.6
  Unknown6686.8
Clinicopathological features of reactive lymphoid hyperplasia of the liver Etiology and pathogenesis of RLH of the liver is not fully understood. Many patients with RLH of the liver have liver disease, autoimmune disease, or a malignant tumor. It is speculated that RLH is related to a reactive immunological response to a chronic inflammatory process. Nakabayashi et al. reported that tumor growth factor-β knockout mice showed multiple lymphoproliferative disorders similar to those observed in the pseudolymphoma of Sjögren’s syndrome, and that upregulation of several inflammatory cytokine genes, interferon-γ, interleukin (IL)-1, IL-6, and IL-10, was observed in their salivary glands [52]. Up/downregulation of some cytokines and chemokines are strongly associated with cancer growth and progression [53]. Many cases of RLH of the liver have a history of malignant tumors; cytokines and chemokines derived from the malignant tumors may affect the occurrence of RLH. The imaging findings of RLH are nonspecific and varied from strongly enhanced, slightly enhanced, to perinodularly enhanced on contrast CT and MRI. Thus, it is extremely difficult to differentiate hepatic RLH from malignant tumors such as HCC and CCC and metastatic tumors based on imaging findings alone. Indeed, surgical resections were performed for the diagnosis of these malignancies in many cases. The nodule increased in size in some cases, including ours [8, 34, 48], but in other cases, it reduced without any treatment [14, 27]. Additionally, malignant conversion has been reported in the lungs, stomach, and skin [54-56]. In RLH of the liver, only one case transformed into mucosa-associated lymphoid tissue lymphoma [57]. Therefore, we think that pathological diagnosis by needle biopsy and intensive follow-up is warranted. Histologically, RLH of the liver consists of hyperplastic lymphoid follicles, lymphocytes, and other inflammatory cells. Immunohistochemical staining is positive for B cell markers (CD20 or CD79α) and T cell markers (CD3 or CD4), indicating polyclonality. CD20-positive B cells are predominantly located in the lymphoid follicles and CD3-positive T cells are predominantly located in interfollicular areas. Additionally, the lymphocytes in the germinal centers are negative for Bcl-2, which indicates the non-neoplastic and reactive nature [30]. Some reported that portal venular disappearance and/or stenosis, caused by marked lymphoid cell infiltration in the portal tracts around nodules, was observed in the perinodular lesion [22, 27, 31, 57, 58]. These pathological changes may induce portal flow disturbances and increased hepatic arterial flow in the perinodular lesion, resulting in perinodular enhancement. A similar finding was found in the present case. In a meta-analysis [59], the pooled HCC incidence rate in AIH patients without cirrhosis was 1.14 per 1000 person-years and 10.07 per 1000 person-years in AIH patients with cirrhosis, which was lower than viral hepatitis such as hepatitis B or C. When a nodule is detected in a patient with AIH, we should consider the possibility of RLH of the liver.

Conclusions

We presented a case of RLH of the liver associated with AIH and performed a sectionectomy with the presumptive diagnosis of HCC. However, the lesion was found to be a benign RLH upon pathological and histochemical examination of the resected specimen. The pathogenesis of RLH of the liver remains unknown, and a definitive diagnosis based on imaging findings is extremely difficult. If a small, solitary nodule is found in female patients with AIH, the possibility of RLH of the liver should be considered.
  59 in total

Review 1.  Reactive lymphoid hyperplasia of the liver: literature review and 3 case reports.

Authors:  Kiyoshi Yoshikawa; Masaru Konisi; Taira Kinoshita; Shinichiro Takahashi; Naoto Gotohda; Yuichiro Kato; Motohiro Kojima
Journal:  Hepatogastroenterology       Date:  2011 Jul-Aug

2.  MR imaging of reactive lymphoid hyperplasia of the liver.

Authors:  Akihiko Kobayashi; Tatsuya Oda; Kiyoshi Fukunaga; Ryoko Sasaki; Manabu Minami; Nobuhiro Ohkohchi
Journal:  J Gastrointest Surg       Date:  2011-02-18       Impact factor: 3.452

3.  Reactive lymphoid hyperplasia of the liver mimicking hepatocellular carcinoma: incidental finding of two cases.

Authors:  Ang Lv; Wendy Liu; Hong-Gang Qian; Jia-Hua Leng; Chun-Yi Hao
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 4.  Reactive lymphoid hyperplasia of the liver and pancreas. A report of two cases and a comprehensive review of the literature.

Authors:  Aimen Amer; Sebastian Mafeld; Danish Saeed; Wissam Al-Jundi; Beate Haugk; Richard Charnley; Steven White
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-01-09       Impact factor: 2.947

5.  Reactive lymphoid hyperplasia of the liver characterized by an angiofollicular pattern mimicking Castleman's disease.

Authors:  T Tanizawa; Y Eishi; R Kamiyama; M Nakahara; Y Abo; T Sumita; N Kawano
Journal:  Pathol Int       Date:  1996-10       Impact factor: 2.534

6.  Hepatic pseudolymphoma: imaging features on dynamic contrast-enhanced MRI and diffusion-weighted imaging.

Authors:  Yang Zhou; XiaoLin Wang; Chen Xu; GuoFeng Zhou; MengSu Zeng; PengJu Xu
Journal:  Abdom Radiol (NY)       Date:  2018-09

Review 7.  Gastric pseudolymphoma. Its three subtypes and relation to lymphoma.

Authors:  J J Brooks; H T Enterline
Journal:  Cancer       Date:  1983-02-01       Impact factor: 6.860

Review 8.  Pseudolymphoma of the liver: Report of a case and review of the literature.

Authors:  Cheng-Ta Yang; Kao-Lang Liu; Ming-Chieh Lin; Ray-Hwang Yuan
Journal:  Asian J Surg       Date:  2013-08-23       Impact factor: 2.767

9.  'Pseudolymphoma'. A case associated with primary immunodeficiency disease and polyglandular failure syndrome.

Authors:  D C Snover; A H Filipovich; L P Dehner; W Krivit
Journal:  Arch Pathol Lab Med       Date:  1981-01       Impact factor: 5.534

10.  A case of hepatic pseudolymphoma in a patient with primary biliary cirrhosis.

Authors:  Masashi Inoue; Masahiro Tanemura; Tomio Yuba; Tatsuya Miyamoto; Megumi Yamaguchi; Toshimitsu Irei; Shingo Seo; Toshihiro Misumi; Wataru Shimizu; Takahisa Suzuki; Takashi Onoe; Takeshi Sudo; Yosuke Shimizu; Takao Hinoi; Hirotaka Tashiro
Journal:  Clin Case Rep       Date:  2019-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.